James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.
James Howard, MD
Advertisement
Articles by James Howard, MD
James F. Howard, MD, discusses the significance of the FDA expanding the label for efgartigimod in patients with generalized myasthenia gravis (gMG).
A retrospective analysis of Medicare claims was used to study emergency department (ED) dispositions, specifically evaluating inpatient admissions compared with home health referrals.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5